Lung Cancer


Share

Program Content

Activities

  • EVOKE 01
    EVOKE-01: Phase III Trial of Sacituzumab Govitecan vs Docetaxel in Patients With Previously Treated Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2024

    Expires: June 01, 2025

  • CROWN 5 Yr Update
    Phase III CROWN: 5-Yr Update of First-line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2024

    Expires: June 02, 2025

  • KRYSTAL 12
    KRYSTAL-12: Phase III Trial of Adagrasib vs Docetaxel in Previously Treated Advanced KRASG12C- Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • LAURA: Osimertinib Consolidation
    LAURA: Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • ADRIATIC
    ADRIATIC: Phase III Trial of Consolidation Therapy With Durvalumab for Limited-Stage Small-Cell Lung Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • DESTINY Lung02 Final Analysis
    DESTINY-Lung02: Final Analysis of Trastuzumab Deruxtecan in Previously Treated HER2-Mutated Metastatic NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • PALOMA-3 SC Amivantamab
    PALOMA-3: Phase III Noninferiority Trial of SC Amivantamab vs IV Amivantamab Each With Lazertinib in Progressive Advanced EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • Beamion LUNG 1
    Beamion LUNG-1 Phase Ia/Ib Study: Updated Results of HER2 TKI Zongertinib in Patients With Advanced NSCLC or Other Solid Tumors With HER2 Aberrations
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • WU KONG1
    WU-KONG1: Primary Analysis of a Phase II Study of Sunvozertinib in Patients With Previously Treated Advanced NSCLC and an EGFR Exon 20 Insertion Mutations
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • REACH PC
    REACH PC: A Comparison of Efficacy of Telehealth vs In-Person Visits for Delivery of Early Palliative Care for Patients With Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2024

    Expires: June 06, 2025

  • ASCO to Clinic: Lung Cancers
    Conference to Clinic: Lung Cancers
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 21, 2024

    Expires: June 20, 2025

  • ASCO 2024 lung cancer WC
    Conference to Clinic: Lung Cancer
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 02, 2024

    Expires: July 01, 2025

  • ASCO 2024: Lung Cancer
    Conference to Clinic: Expert Analysis of the Top Abstracts in Lung Cancer From the 2024 Oncology Meeting in Chicago
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 23, 2024

    Expires: February 22, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.